{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "New York",
      "state": "NY",
      "country": "United States",
      "classification": "Class II",
      "openfda": {
        "application_number": [
          "NDA021301"
        ],
        "brand_name": [
          "LEVOXYL"
        ],
        "generic_name": [
          "LEVOTHYROXINE SODIUM"
        ],
        "manufacturer_name": [
          "Pfizer Laboratories Div Pfizer Inc"
        ],
        "product_ndc": [
          "60793-850",
          "60793-851",
          "60793-852",
          "60793-853",
          "60793-854",
          "60793-855",
          "60793-856",
          "60793-857",
          "60793-858",
          "60793-859",
          "60793-860"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "LEVOTHYROXINE SODIUM"
        ],
        "rxcui": [
          "892246",
          "892251",
          "966157",
          "966164",
          "966170",
          "966175",
          "966184",
          "966190",
          "966194",
          "966200",
          "966204",
          "966211",
          "966220",
          "966221",
          "966222",
          "966224",
          "966225",
          "966248",
          "966249",
          "966253",
          "966270",
          "966283"
        ],
        "spl_id": [
          "e230c170-2a16-47d0-bce7-ac0414c192f7"
        ],
        "spl_set_id": [
          "758588c3-c63e-491b-0aa2-4f50d80cb174"
        ],
        "package_ndc": [
          "60793-850-10",
          "60793-850-01",
          "60793-851-10",
          "60793-851-01",
          "60793-852-10",
          "60793-852-01",
          "60793-853-10",
          "60793-853-01",
          "60793-854-10",
          "60793-854-01",
          "60793-855-10",
          "60793-855-01",
          "60793-856-10",
          "60793-856-01",
          "60793-857-10",
          "60793-857-01",
          "60793-858-10",
          "60793-858-01",
          "60793-859-10",
          "60793-859-01",
          "60793-860-10",
          "60793-860-01"
        ],
        "is_original_packager": [
          true
        ],
        "upc": [
          "0360793856018",
          "0360793850016",
          "0360793852010",
          "0360793851013",
          "0360793857015",
          "0360793853017",
          "0360793854014",
          "0360793858012",
          "0360793855011",
          "0360793859019",
          "0360793860015"
        ],
        "unii": [
          "9J765S329G"
        ]
      },
      "product_type": "Drugs",
      "event_id": "75691",
      "recalling_firm": "Pfizer Inc.",
      "address_1": "235 East 42nd Street",
      "address_2": "N/A",
      "postal_code": "10017-5703",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide",
      "recall_number": "D-0150-2017",
      "product_description": "LEVOXYL(R) (levothyroxine sodium tablets, USP), 200 mcg, 100 count bottles, Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN 37620, NDC 60793-860-01",
      "product_quantity": "2,666 bottles",
      "reason_for_recall": "Superpotent",
      "recall_initiation_date": "20161107",
      "center_classification_date": "20161123",
      "termination_date": "20200501",
      "report_date": "20161130",
      "code_info": "16H21, Exp. 08/2017"
    }
  ]
}